Compare · AVNS vs ZBH
AVNS vs ZBH
Side-by-side comparison of Avanos Medical Inc. (AVNS) and Zimmer Biomet Holdings Inc. (ZBH): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AVNS and ZBH operate in Industrial Specialties (Health Care), so they compete in similar markets.
- ZBH is the larger of the two at $19.12B, about 16.3x AVNS ($1.17B).
- ZBH has been more active in the news (7 items in the past 4 weeks vs 1 for AVNS).
- ZBH has more recent analyst coverage (25 ratings vs 7 for AVNS).
- Company
- Avanos Medical Inc.
- Zimmer Biomet Holdings Inc.
- Price
- $24.99+0.04%
- $100.18-0.67%
- Market cap
- $1.17B
- $19.12B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NYSE
- IPO
- 2014
- News (4w)
- 1
- 7
- Recent ratings
- 7
- 25
Avanos Medical Inc.
Avanos Medical, Inc. operates as a medical technology company that focuses on delivering medical device solutions to improve patients' quality of life in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions; and respiratory health products, such as closed airway suction systems and other airway management devices under the Ballard, Microcuff, and Endoclear brands. The company also provides a portfolio of non-opioid pain solutions, including acute pain products, such as On-Q and ambIT surgical pain pumps and Game Ready cold and compression therapy systems; and interventional pain solutions, which offers minimally invasive pain relieving therapies, such as Coolief pain relief therapy. It markets its products directly to hospitals and other healthcare providers, healthcare facilities, and other end-user customers, as well as through third-party wholesale distributors. The company was formerly known as Halyard Health, Inc. and changed its name to Avanos Medical, Inc. in June 2018. Avanos Medical, Inc. was incorporated in 2014 and is headquartered in Alpharetta, Georgia.
Zimmer Biomet Holdings Inc.
Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products, as well as surgical, bone cement, and office-based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.
Latest AVNS
- SEC Form 15-12G filed by Avanos Medical Inc.
- SEC Form S-8 POS filed by Avanos Medical Inc.
- Avanos Medical Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Creation of a Direct Financial Obligation, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits
- SVP, Operations Delgado Sigfrido returned $2,765,675 worth of shares to the company (110,627 units at $25.00) and was granted 54,886 shares, closing all direct ownership in the company (SEC Form 4) (tax liability)
- SVP, Chief Financial Officer Galovan Scott Michael returned $5,792,925 worth of shares to the company (231,717 units at $25.00) and was granted 96,121 shares, closing all direct ownership in the company (SEC Form 4) to satisfy tax liability
- Chief Executive Officer Pacitti David returned $19,173,100 worth of shares to the company (766,924 units at $25.00) and was granted 444,730 shares, closing all direct ownership in the company (SEC Form 4) (tax liability)
- Director Shimer Julie Ann returned $1,252,250 worth of shares to the company (50,090 units at $25.00), closing all direct ownership in the company (SEC Form 4) to cover taxes
- Director Oleary Patrick J returned $1,366,000 worth of shares to the company (54,640 units at $25.00), closing all direct ownership in the company (SEC Form 4) (for tax liability)
- Director Franchini Indrani Lall returned $120,425 worth of shares to the company (4,817 units at $25.00), closing all direct ownership in the company (SEC Form 4) (for withholding tax)
- Director Egbuonu-Davis Lisa returned $345,275 worth of shares to the company (13,811 units at $25.00), closing all direct ownership in the company (SEC Form 4) (for tax liability)
Latest ZBH
- Amendment: SEC Form SCHEDULE 13G/A filed by Zimmer Biomet Holdings Inc.
- Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 4 filed by President, APAC Desai Chintan
- SEC Form 10-Q filed by Zimmer Biomet Holdings Inc.
- Zimmer Biomet Holdings Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Zimmer Biomet Announces Second Quarter 2026 Financial Results
- Grp Pres-Global Business Thornal Kevin R converted options into 9,957 shares and covered exercise/tax liability with 4,266 shares (SEC Form 4) (tax liability)
- UBS initiated coverage on Zimmer Biomet with a new price target
- SEC Form 3 filed by new insider Desai Chintan
- Zimmer Biomet Names Chintan Desai President of Asia Pacific Region